Summit Therapeutics revenue and financials
$17.31Change from previous close: +0.23%Absolute change: +$0.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -141 | -122 | -102 | -93.1 | -66.7 | -61.2 | -48.7 | -30.3 | -33.0 | -30.1 | -19.5 | -14.9 |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital expenditure | -0.9 | -0.2 | -0.2 | -0.1 | — | -0.4 | -0.0 | -0.1 | -0.1 | -0.0 | -0.0 | -0.1 |
| Investing cash flow | 223 | -0.2 | -485 | -0.1 | 151 | 160 | 83.5 | -109 | -200 | 19.9 | 60.6 | -3.5 |
| Financing cash flow | 231 | 3.8 | 574 | 33.8 | 2.2 | 7.7 | -23.6 | 204 | 200 | 0.5 | 6.3 | 0.2 |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | -0.4 |
| Debt repaid | — | — | 0.0 | — | — | — | -24.5 | -75.5 | — | — | — | — |
| Effect of exchange rates | 0.0 | -0.0 | -0.0 | 0.0 | 0.1 | 0.0 | -0.1 | 0.1 | 0.0 | -0.0 | 0.3 | -0.2 |
| Net change in cash | 313 | -119 | -13.3 | -59.3 | 86.3 | 107 | 11.1 | 65.3 | -32.9 | -9.8 | 47.6 | -18.3 |
| Free cash flow | -142 | -123 | -102 | -93.2 | -66.7 | -61.6 | -48.7 | -30.4 | -33.1 | -30.1 | -19.5 | -15.0 |
| Levered free cash flow | -62.1 | -49.9 | -20.5 | -7.2 | 147 | -35.7 | -30.8 | -39.5 | 1.2 | -19.9 | -6.5 | -5.4 |